N4 Pharma PLC EPO Patent Granted (6181N)
01 October 2021 - 3:59PM
UK Regulatory
TIDMN4P
RNS Number : 6181N
N4 Pharma PLC
01 October 2021
1 October 2021
N4 Pharma Plc
("N4 Pharma" or the "Company")
EPO Patent Granted
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to announce that further to the Company's
announcement dated 11 February 2021 in which it was stated that the
European Patent Office ("EPO") had notified the Company of its
intention to grant a European patent in relation to Nuvec(R)
specifically in respect of its composition, particulate materials
and methods for making the particulate materials (the "Patent"),
the EPO has now granted this Patent which has been validated in the
main territories across Europe*. This Patent adds to existing
grants in Australia and Japan.
The Company is also pleased to announce that it has been
informed by the Chinese Patent Office ("CPO") of its intention to
grant the Patent in China in relation to Nuvec(R).
Discussions with other key patent authorities in the US, Canada
and India are continuing and updates will be provided by the
Company on these in due course.
Nigel Theobald, Chief Executive Officer of the Company,
commented : "We are delighted that the EPO has now formally granted
the European Patent which is now validated across Europe. This
achieves another key step in our IP strategy where we are also
making excellent progress following the notice of allowance made
recently by the CPO for the potentially huge market of China and
the ongoing discussions in other key jurisdictions. We look forward
to updating the market on these in due course."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 which has been
incorporated into UK law by the European Union (Withdrawal) Act
2018. Upon the publication of this announcement via Regulatory
Information Service, this inside information is now considered to
be in the public domain.
*European territories validated are: United Kingdom, France,
Germany, Spain, Italy, Netherlands, Switzerland, Sweden, Denmark,
Ireland, Malta, Belgium, Portugal, Norway, Poland
Enquiries:
N4 Pharma Plc Via IFC Advisory
Nigel Theobald, CEO
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: + 44 (0)20 3470 0470
Nominated Adviser and Joint
Broker
Matthew Johnson/Caroline Rowe
(Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
Turner Pope Investments (TPI) Tel: +44 (0)20 3657 0050
Limited
Joint Broker
Andy Thacker
IFC Advisory Limited Tel: +44 (0)20 3934 6630
Financial PR
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FURURUVRAKUKOAR
(END) Dow Jones Newswires
October 01, 2021 01:59 ET (05:59 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Mar 2024 to Apr 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2023 to Apr 2024